ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för linagliptin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

74 träffar

Bibliografisk träff 2012-10-01

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.

Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/dom.12011

Bibliografisk träff 2012-10-01

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.

McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ.

Diabetes Care · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.2337/dc12-0706

Bibliografisk träff 2012-09-18

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.

Rauch T, Graefe-Mody U, Deacon CF, Ring A, Ring A, Holst JJ, Woerle HJ, Dugi KA, Heise T.

Diabetes Ther · research-article; journal article · DOI 10.1007/s13300-012-0010-y

Bibliografisk träff 2012-09-01

Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.

Chen L, Klein T, Leung PS.

Curr Mol Med · research support, non-u.s. gov't; journal article · DOI 10.2174/156652412802480970

Bibliografisk träff 2012-09-01

Linagliptin: a review of its use in the management of type 2 diabetes mellitus.

Deeks ED.

Drugs · review; journal article · DOI 10.2165/11209570-000000000-00000

Bibliografisk träff 2012-08-29

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ.

Clin Ther · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.clinthera.2012.07.008

Bibliografisk träff 2012-08-28

Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?

Christensen M, Knop FK.

Nat Rev Endocrinol · news · DOI 10.1038/nrendo.2012.163

Bibliografisk träff 2012-08-13

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.

Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ.

Curr Med Res Opin · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1185/03007995.2012.714360

Bibliografisk träff 2012-07-03

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.

Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T.

J Endocrinol · research support, non-u.s. gov't; journal article · DOI 10.1530/joe-11-0479

Bibliografisk träff 2012-07-01

Pharmacokinetics of linagliptin in subjects with hepatic impairment.

Graefe-Mody U, Rose P, Retlich S, Ring A, Ring A, Waldhauser L, Cinca R, Woerle HJ.

Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1365-2125.2012.04173.x

Bibliografisk träff 2012-07-01

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

Graefe-Mody U, Retlich S, Friedrich C.

Clin Pharmacokinet · research support, non-u.s. gov't; review; journal article · DOI 10.2165/11630900-000000000-00000

Bibliografisk träff 2012-06-28

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ.

Lancet · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(12)60691-6

Bibliografisk träff 2012-06-25

Evaluation of body fat composition after linagliptin treatment in a rat model of diet-induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine.

Klein T, Niessen HG, Ittrich C, Mayoux E, Mueller HP, Cheetham S, Stiller D, Kassubek J, Mark M.

Diabetes Obes Metab · letter; comparative study; research support, non-u.s. gov't · DOI 10.1111/j.1463-1326.2012.01629.x

Bibliografisk träff 2012-06-22

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity.

Kern M, Klöting N, Niessen HG, Thomas L, Stiller D, Mark M, Klein T, Blüher M.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0038744

Bibliografisk träff 2012-06-12

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.

Gomis R, Owens DR, Taskinen MR, Del Prato S, Patel S, Pivovarova A, Schlosser A, Woerle HJ.

Int J Clin Pract · journal article · DOI 10.1111/j.1742-1241.2012.02975.x

Bibliografisk träff 2012-06-01

Linagliptin: a novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor.

Agrawal R, Jain P, Dikshit SN.

Curr Drug Targets · review; journal article · DOI 10.2174/138945012800675731

Bibliografisk träff 2012-05-16

Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea.

Aronson R.

Expert Opin Pharmacother · comment; journal article · DOI 10.1517/14656566.2012.689825

Bibliografisk träff 2012-05-01

The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety.

Wright S, Singh RP, Retlich S, Graefe-Mody U, Derendorf H.

Int J Clin Pharmacol Ther · research support, non-u.s. gov't; journal article · DOI 10.5414/cp201630

Bibliografisk träff 2012-04-04

The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.

Schürmann C, Linke A, Engelmann-Pilger K, Steinmetz C, Mark M, Pfeilschifter J, Klein T, Frank S.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.111.191098

Bibliografisk träff 2012-04-01

[Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].

Ohmura T, Hayashi N, Encinas J.

Nihon Yakurigaku Zasshi · review; journal article · DOI 10.1254/fpj.139.174

Bibliografisk träff 2012-03-21

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ.

Diabetes Obes Metab · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2012.01590.x

Bibliografisk träff 2012-03-21

Review of linagliptin for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Setter SM.

Clin Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.clinthera.2012.02.029

Bibliografisk träff 2012-03-20

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C.

Diabetes Obes Metab · meta-analysis; systematic review; journal article · DOI 10.1111/j.1463-1326.2012.01586.x

Bibliografisk träff 2012-02-16

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.

Schernthaner G, Barnett AH, Emser A, Patel S, Troost J, Woerle HJ, von Eynatten M.

Diabetes Obes Metab · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1463-1326.2012.01565.x

Bibliografisk träff 2012-02-07

Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.

Neumiller JJ.

Ann Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1345/aph.1q522

Bibliografisk träff 2012-02-01

[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].

Scheen AJ, Van Gaal LF.

Rev Med Liege · journal article; english abstract

Bibliografisk träff 2012-01-17

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.

Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, Sarashina A, Gong Y, von Eynatten M, Woerle HJ, Dugi KA.

Diabetes Obes Metab · clinical trial, phase iii; clinical trial, phase ii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1463-1326.2011.01545.x

Bibliografisk träff 2012-01-11

Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.

Gallwitz B.

Clin Med Insights Endocrinol Diabetes · review-article; journal article · DOI 10.4137/cmed.s7274

Bibliografisk träff 2012-01-10

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ.

Cardiovasc Diabetol · meta-analysis; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1475-2840-11-3

Bibliografisk träff 2012-01-02

The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats.

Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T.

Int J Cardiol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ijcard.2011.12.007